Sakai H, Diener M, Gartmann V, Takeguchi N
Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Japan.
Naunyn Schmiedebergs Arch Pharmacol. 1995 Mar;351(3):309-14. doi: 10.1007/BF00233252.
Irinotecan (CPT-11) is active against a broad range of human cancer. One of the side-effects of irinotecan is a strong diarrhoea. In order to investigate the mechanism underlying this diarrhoea, the effect of irinotecan on anion secretion across the isolated rat distal colon was studied. Irinotecan caused a concentration-dependent increase in short-circuit current (Isc). The increase in Isc was completely dependent on the presence of Cl- ions and was suppressed by furosemide and the Cl- channel blocker NPPB (5-nitro-2-(3-phenylpropylamino)-benzoate), indicating that it is caused by a Cl- secretion. The secretory response was inhibited by indomethacin, 1-benzylimidazole, a thromboxane synthase inhibitor, and SK&F 88046 ((N,N'-bis[7-(3-Chlorobenzeneaminosulfonyl)-1,2,3,4-tetrahydroi soquinolyl) disulfonylimide), a thromboxane A2 receptor blocker. In isolated crypts irinotecan had no effect on the membrane potential. Consequently, the secretion induced by irinotecan is an indirect one, caused by the stimulation of eicosanoid production, e.g. thromboxane A2, in the subepithelial tissue.
伊立替康(CPT - 11)对多种人类癌症具有活性。伊立替康的副作用之一是严重腹泻。为了研究这种腹泻的潜在机制,研究了伊立替康对离体大鼠远端结肠阴离子分泌的影响。伊立替康导致短路电流(Isc)呈浓度依赖性增加。Isc的增加完全依赖于Cl⁻离子的存在,并被呋塞米和Cl⁻通道阻滞剂NPPB(5 - 硝基 - 2 -(3 - 苯基丙基氨基) - 苯甲酸酯)抑制,表明这是由Cl⁻分泌引起的。分泌反应被吲哚美辛、血栓素合酶抑制剂1 - 苄基咪唑和血栓素A2受体阻滞剂SK&F 88046((N,N'-双[7 -(3 - 氯苯氨基磺酰基) - 1,2,3,4 - 四氢异喹啉基]二磺酰亚胺)抑制。在离体隐窝中,伊立替康对膜电位没有影响。因此,伊立替康诱导的分泌是间接的,由上皮下组织中类花生酸产物(如血栓素A2)的刺激引起。